SPRUCE BIOSCIENCES, INC.
SPRB · XNASCIK 1683553fmd_1ZA7MF4ZZ5WYH55WFKXT35AAEYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 10 | 5 | 0 |
| Research and development | 11 | 24 | 31 | 35 | 49 | 46 | 20 |
| Total operating expenses | 13 | 29 | 42 | 47 | 62 | 61 | 37 |
| Operating income | (13) | (29) | (42) | (47) | (52) | (56) | (37) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | 0 | 2 | 5 | 3 | 1 |
| Other non-operating income (expense) | 0 | 0 | 0 | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (13) | (30) | (42) | (46) | (48) | (53) | (39) |